Enochian Biosciences Inc - FORM 10-K - EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION - September 28, 2018

Attached files

file filename
10-K - FORM 10-K - Enochian Biosciences Ince1146_form10k.htm
EX-32.2 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION - Enochian Biosciences Ince1146_32-2.htm
EX-31.2 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES - Enochian Biosciences Ince1146_31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES - Enochian Biosciences Ince1146_31-1.htm
EX-21 - SUBSIDIARIES - Enochian Biosciences Ince1146_21.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Dandrit Biotech USA, Inc. (the “Company”) on Form 10-K for the year ending June 30, 2018 as filed with the Securities and Exchange Commission (the “Report”), the undersigned, Eric Leire, as Chief Executive Officer (Principal Executive Officer) of the Company, hereby certifies as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge: 

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: October 1, 2018  
   
/s/ Eric Leire  
Eric Leire  
Chief Executive Officer
(Principal Executive Officer) 		 

 

 

Enochian Biosciences Inc Reports